Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma

NCT ID: NCT01370135

Last Updated: 2013-01-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-11-30
• Study Completion Date: 2011-07-31

Brief Summary

Proliferative ischemic retinopathies lead to a formation of abnormal vessels on the iris surface induced by an increased level of vascular endothelial growth factor (VEGF). In progressive stages fibrovascular membranes occlude the anterior chamber angle which inhibits aqueous outflow resulting in neovascular glaucoma. The increased intraocular pressure is often difficult to control and frequently results in loss of vision.

The aim of this study is to analyze the short- and long-term outcome after adjuvant intraocular Ranibizumab application in patients with neovascular glaucoma and rubeosis and to analyze the role of ranibizumab within a holistic treatment regime.

Conditions

Neovascular Glaucoma; Rubeosis

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Lucentis (Ranibizumab)

Group Type: EXPERIMENTAL

0.5mg intraocular Ranibizumab (Lucentis)

Intervention Type: DRUG

short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections as adjuvant for patients with rubeosis and neovascular glaucoma

Interventions

0.5mg intraocular Ranibizumab (Lucentis)

short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections as adjuvant for patients with rubeosis and neovascular glaucoma

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. neo-vascular glaucoma or rubeosis

• definition of neo-vascular glaucoma: patient with iris neovascularization with intraocular pressure elevation (exceeding 21 mmHg)
• definition of rubeosis: patient with iris neovascularization without intraocular pressure elevation (≤21 mmHg)

2. an available follow-up of 12 months

3. written informed consent

4. visual acuity of light perception or better.

Exclusion Criteria

1. history or evidence of severe cardiac disease (e.g., NYHA functional class III or IV)

2. clinical or medical history of unstable angina, acute coronary syndrome, myocardial infarction or revascularization with 6 months

3. ventricular tachyarrhythmias requiring ongoing treatment

4. History or evidence clinically significant peripheral vascular disease, such as intermittent claudication or prior amputation

5. Clinically significant impaired renal or hepatic function

6. Stroke within 12 month before trial entry.

7. Known serious allergies to the fluorescein dye use in angiography

8. Known contraindications to the components of Lucentis® formulation.

Ocular concomitant conditions/ diseases

1. Active intraocular inflammation (grade trace or above) in either eye

2. Any active infection (e.g. conjunctivitis, keratitis, scleritis, uveitis, endophthalmitis) in either eye

3. History of uveitis in either eye

4. Treatment with anti-angiogenic drugs (pegaptanib sodium, anecortave acetate,bevacizumab, ranibizumab, etc.) or intravitreal corticosteroids in either eye within 4 months prior to inclusion

5. Angle block glaucoma

6. Phthisis

7. Intraocular Pressure <10mmHg

Compliance/ Administrative

1. Previous participation in any clinical studies of investigational drugs (excluding vitamins and minerals) within 1 month (or a period corresponding to 5 half-lives of the investigational drug, whatever is longer) prior to inclusion

2. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant. including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they are using two birth control methods. The two methods can be a double barrier method or a barrier method plus a hormonal method. Adequate barrier methods of contraception include: diaphragm, condom (by the partner), intrauterine device (copper or hormonal), sponge or spermicide. Hormonal contraceptives include any marketed contraceptive agent that includes an estrogen and/or a progestational agent.

3. Pregnant or nursing (lactating) women

4. Inability to comply with study or follow-up procedures.

5. Any treatment with an investigational agent in the past 60 days for any condition.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Luebeck

OTHER

Sponsor Role: lead

Responsible Party

Dr. Julia Lueke

Dr. med. Julia Lüke

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Salvatore Grisanti, M.D. Prof.

Role: PRINCIPAL_INVESTIGATOR

University of Lübeck - Department of Ophthalmology: Germany

Locations

University of Lübeck - Department of Ophthalmology

Lübeck, , Germany

Countries

Germany

References

Luke J, Nassar K, Luke M, Grisanti S. Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma--results from a prospective interventional case series. Graefes Arch Clin Exp Ophthalmol. 2013 Oct;251(10):2403-13. doi: 10.1007/s00417-013-2428-y. Epub 2013 Jul 28.

Reference Type: DERIVED

PMID: 23893090 (View on PubMed)

Related Links

http://www.uksh.de/Augenklinik_Luebeck/index.html

University of Lübeck - Department of Ophthalmology - Germany

Other Identifiers

LucNVG0108

Identifier Type: -

Identifier Source: org_study_id